molybdate (molybdate ion)

08/01/1989 - "Binding studies with 16-alpha-iodooestradiol using breast cancer tissue cytosols followed by immunoprecipitation showed activity only with oestrogen-receptor positive cytosols with optimal binding activity at 4 degrees C, unaffected by molybdate, but reduced at 25 degrees C or in the presence of 0.4 M KCl. "
12/15/1989 - "Molybdate-stabilized androgen receptors have been quantitated in cytosols derived from 1026 malignant breast tumors including all new cases of primary breast cancer reported in the western region of Norway during the 3-year period 1985-1987. "
09/15/1983 - "To further test the diversity in ER activation, DNA-cellulose binding of ER from 10 primary breast cancer tissues was determined in the presence or absence of molybdate. "
12/01/1981 - "Structural similarity of molybdate-stabilized steroid receptors in human breast tumors, uteri and leukocytes."
04/01/1981 - "Human breast tumor estrogen receptor: effects of molybdate and electrophoretic analyses."

12/01/2001 - "The efficacy of a molybdate formulation and a zinc oxide bolus as prophylactic agents for enzootic icterus was evaluated in sheep. "
12/01/2001 - "Evaluation of a commercially available molybdate formulation and zinc oxide boluses in preventing hepatic copper accumulation and thus enzootic icterus in sheep."
09/01/1975 - "Jaundice and mild hemolysis are noninterferencts and turbidity from severe lipemia is easily overcome by reversing the sequence in which reagents are added because citrate binds molybdate in preference to phosphate. "

01/01/1990 - "Some of the most interesting positive results observed include 4-hydroxyphenyl retinamide plus tamoxifen in breast cancer, piroxicam in colon cancer, dimethylfluoroornithine in breast and bladder cancer, oltipraz in lung cancer, dehydroepiandrosterone in colon cancer, and molybdate in bladder cancer. "

01/01/1990 - "Some of the most interesting positive results observed include 4-hydroxyphenyl retinamide plus tamoxifen in breast cancer, piroxicam in colon cancer, dimethylfluoroornithine in breast and bladder cancer, oltipraz in lung cancer, dehydroepiandrosterone in colon cancer, and molybdate in bladder cancer. "

04/01/1983 - "Tellurite ion offered only 20% protection, while ferrous, zinc, lead, chromic, molybdate, tungstate, and vanadate ions provided no protection against selenium-induced cataract. "